Get the SPI Wire

AETHLON MEDICAL, INC.

NASDAQ:AEMD
Annual Meeting

of Shareholders

MEETING DATE

10/01/2026
DEF 14A FILED
09/01/2026
PUBLISHED
08/31/2026 10:46 pm
TIME TO PUBLISH
09/02/2026
METHODOLOGY
approve
EXCHANGE NASDAQ:AEMD · CUSIP 00808Y703 · CLASS common stock · CIK 0000882291

RECONCILED · MIXED

Reconciled against the company’s Form 8-K Item 5.07 filed 2026-06-15.

6
FOR
4
AGAINST
0
WITHHOLD
10
BALLOT ITEMS

ITEM-BY-ITEM RECOMMENDATIONS

1
To elect five persons named in the Proxy Statement that accompanies this notice to serve as directors of our Company.
board
Contested
For
Board FOR · Duopoly unknown — No divergence flagged

Filing discloses no director-specific legal proceedings or governance concerns.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
2
To ratify the appointment of Haskell & White LLP as our independent registered public accounting firm for the fiscal year ending March 31, 2027.
auditor
Contested
For
Board FOR · Duopoly unknown — No divergence flagged

Audit Committee selected Haskell & White LLP and approved all billed services.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
3
To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of the Company's common stock issuable upon the exercise of the Common Warrants and Placement Agent Warrants issued in connection with the Company's July 2026 registered public offering.
other
Contested
For
Board FOR · Duopoly unknown — No divergence flagged

Approval permits issuance of common stock upon exercise of specified July 2026 warrants.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
4
To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the Proxy Statement.
compensation
Contested
For
Board FOR · Duopoly unknown — No divergence flagged

Filing discloses advisory approval of named executive officer compensation as presented.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
5
To approve an amendment to the Company's 2020 Equity Incentive Plan, as amended, to increase the number of shares of the Company's common stock authorized for issuance thereunder by 100,000 shares.
compensation
Contested
For
Board FOR · Duopoly unknown — No divergence flagged

Filing states the amendment increases authorized shares under the 2020 Equity Incentive Plan by 100,000.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
6
To approve an amendment to the Company’s Articles of Incorporation to increase the number of authorized shares of our common stock from 20,000,000 to 100,000,000
other
Contested
Against
Board FOR · Duopoly unknown — ⚠ Divergence flagged

Filing states future issuances could dilute stockholders' ownership and voting power.

Divergence: 1 Review status: Approved. Publication ledger and 8-K reconciliation pending.
7
To approve an amendment to the Company's Articles of Incorporation to authorize 20,000,000 shares of preferred stock, par value $0.001 per share, and authorize the Board of Directors to establish one or more series thereof and to fix the designations, powers, preferences, rights, qualifications, limitations and restrictions of each such series.
other
Contested
Against
Board FOR · Duopoly unknown — ⚠ Divergence flagged

Filing states preferred stock could dilute voting power and make acquiring control more difficult.

Divergence: 1 Review status: Approved. Publication ledger and 8-K reconciliation pending.
8
To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of the Company's common stock, or securities convertible into or exercisable for shares of the Company's common stock, in connection with one or more future private financing transactions, as more fully described in the accompanying Proxy Statement.
other
Contested
Against
Board FOR · Duopoly unknown — ⚠ Divergence flagged

Filing states future financing transactions may dilute existing stockholders' ownership interests and voting power.

Divergence: 1 Review status: Approved. Publication ledger and 8-K reconciliation pending.
9
To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of the Company’s common stock, par value $0.001 per share, and/or securities exercisable for shares of the Company’s common stock, in connection with one or more future warrant exercise inducement transactions involving certain of the Company’s outstanding warrants.
other
Contested
Against
Board FOR · Duopoly unknown — ⚠ Divergence flagged

Filing states warrant inducement transactions could result in substantial dilution to existing stockholders.

Divergence: 1 Review status: Approved. Publication ledger and 8-K reconciliation pending.
10
To approve the adjournment of the Annual Meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to approve one or more of the foregoing proposals.
other
Contested
For
Board FOR · Duopoly unknown — No divergence flagged

Proposal permits additional proxy solicitation if votes are insufficient to approve other proposals.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.

Ledger

66359527e738561f37e09c21e081af246051c3ca7e61ab103372f5dd780aba43

Search company, ticker, executive, director or issue

    The SPI Wire · Proxy Intelligence

    Get every ballot call, before the vote.

    FOR, AGAINST or WITHHOLD on each covered ballot item — published within 48 hours of the definitive proxy filing. Follow the companies you own, or take the full feed.




    Pick the companies you own — you’ll only hear from us on their ballots.

    The SPI Wire covers proxy ballots only — it has nothing to do with Signal Research investigations. Research and analysis for informational purposes; not legal, investment, or voting advice. Unsubscribe anytime.

    Submit Information








      Join Monitoring List




        Receive Research Updates